secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001104659-24-119079
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio submits Phase 2 protocol for tibulizumab in systemic sclerosis to FDA
------------------------------------------------------------------------------

- Protocol submitted to open IND for Phase 2 study of tibulizumab (IL-17A/BAFF dual antagonist) in adults with systemic sclerosis.
- Study is double-blind, randomized (1:1), placebo-controlled, targeting ~80 participants with early diffuse cutaneous SSc.
- Trial expected to initiate in Q4 2024; Orphan Drug Designation request also submitted to FDA same quarter.
- Tibulizumab is investigational; no regulatory approval yet for systemic sclerosis or any indication.
- CEO cites significant unmet need as current SSc treatments only target interstitial lung disease component.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924119079/0001104659-24-119079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924119079/tm2428489d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-119079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer